
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1631884/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Transcriptional Landscape of the Mammalian Genome. Science, 2005, 309, 1559-1563.	12.6	3,227
2	Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature, 2002, 420, 563-573.	27.8	1,548
3	Functional annotation of a full-length mouse cDNA collection. Nature, 2001, 409, 685-690.	27.8	653
4	Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14825-14830.	7.1	311
5	Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene, 2004, 23, 7436-7440.	5.9	239
6	Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene, 2013, 32, 1475-1487.	5.9	204
7	A major susceptibility locus to murine lung carcinogenesis maps on chromosome 6. Nature Genetics, 1993, 3, 132-136.	21.4	127
8	Transcriptional network dynamics in macrophage activation. Genomics, 2006, 88, 133-142.	2.9	125
9	miRNA Profiling in Colorectal Cancer Highlights miR-1 Involvement in MET-Dependent Proliferation. Molecular Cancer Research, 2012, 10, 504-515.	3.4	123
10	Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer. British Journal of Cancer, 2014, 110, 1001-1007.	6.4	118
11	Limits of Predictive Models Using Microarray Data for Breast Cancer Clinical Treatment Outcome. Journal of the National Cancer Institute, 2005, 97, 927-930.	6.3	110
12	Metformin transiently inhibits colorectal cancer cell proliferation as a result of either AMPK activation or increased ROS production. Scientific Reports, 2017, 7, 15992.	3.3	102
13	Gold-Nanoparticle-Based Colorimetric Discrimination of Cancer-Related Point Mutations with Picomolar Sensitivity. ACS Nano, 2013, 7, 5530-5538.	14.6	101
14	Multiple Loci Affect Genetic Predisposition to Hepatocarcinogenesis in Mice. Genomics, 1994, 23, 118-124.	2.9	93
15	Challenges in Projecting Clustering Results Across Gene Expression–Profiling Datasets. Journal of the National Cancer Institute, 2007, 99, 1715-1723.	6.3	88
16	Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Research and Treatment, 2011, 127, 601-610.	2.5	88
17	Stearoyl-CoA desaturase 1 (Scd1) gene overexpression is associated with genetic predisposition to hepatocarcinogenesis in mice and rats. Carcinogenesis, 2002, 23, 1933-1936.	2.8	81
18	M AM expression as marker of poor prognosis in epithelial ovarian cancer. International Journal of Cancer, 2006, 119, 1920-1926.	5.1	78

#	Article	IF	CITATIONS
19	Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. Oncogene, 2004, 23, 8171-8183.	5.9	75
20	Misbehaviour of XIST RNA in Breast Cancer Cells. PLoS ONE, 2009, 4, e5559.	2.5	75
21	Mapping of body weight loci on mouse Chromosome X. Mammalian Genome, 1995, 6, 778-781.	2.2	70
22	Gene discovery in genetically labeled single dopaminergic neurons of the retina. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 5069-5074.	7.1	70
23	Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. Annals of Oncology, 2014, 25, 404-408.	1.2	67
24	Genetic mapping of a pulmonary adenoma resistance locus (Par1) in mouse. Nature Genetics, 1996, 12, 455-457.	21.4	64
25	Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma. Laboratory Investigation, 2008, 88, 474-481.	3.7	60
26	miR-342 Regulates BRCA1 Expression through Modulation of ID4 in Breast Cancer. PLoS ONE, 2014, 9, e87039.	2.5	59
27	To Bleed or Not to Bleed. A Prediction Based on Individual Gene Profiling Combined With Dose–Volume Histogram Shapes in Prostate Cancer Patients Undergoing Three-Dimensional Conformal Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1431-1440.	0.8	55
28	DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. British Journal of Clinical Pharmacology, 2015, 80, 581-588.	2.4	52
29	A methodological procedure for evaluating the impact of hemolysis on circulating microRNAs. Oncology Letters, 2017, 13, 315-320.	1.8	52
30	Integrative approach for prioritizing cancer genes in sporadic colon cancer. Genes Chromosomes and Cancer, 2009, 48, 953-962.	2.8	47
31	Role of cMET in the Development and Progression of Colorectal Cancer. International Journal of Molecular Sciences, 2013, 14, 18056-18077.	4.1	47
32	The Effects of miRâ€⊋0a on p21: Two Mechanisms Blocking Growth Arrest in TGFâ€Î²â€Responsive Colon Carcinoma. Journal of Cellular Physiology, 2015, 230, 3105-3114.	4.1	46
33	Effects of Warm Ischemic Time on Gene Expression Profiling in Colorectal Cancer Tissues and Normal Mucosa. PLoS ONE, 2013, 8, e53406.	2.5	44
34	MIF/CD74 axis is a target for novel therapies in colon carcinomatosis. Journal of Experimental and Clinical Cancer Research, 2017, 36, 16.	8.6	43
35	Chromosome band 17q21 in breast cancer: Significant association between <i>beclin 1</i> loss and <i>HER2/NEU</i> amplification. Genes Chromosomes and Cancer, 2010, 49, 901-909.	2.8	41
36	Circulating Free DNA in a Screening Program for Early Colorectal Cancer Detection. Tumori, 2014, 100, 115-121.	1.1	39

#	Article	IF	CITATIONS
37	Molecular predictors of response and outcome in ovarian cancer. Critical Reviews in Oncology/Hematology, 2006, 60, 19-37.	4.4	36
38	Plasma miRNAâ€based signatures in CRC screening programs. International Journal of Cancer, 2020, 146, 1164-1173.	5.1	35
39	Linkage Disequilibrium and Physical Mapping of <i>Pas1</i> in Mice. Genome Research, 1999, 9, 639-646.	5.5	35
40	VE-Cadherin Expression and Clustering Maintain Low Levels of Survivin in Endothelial Cells. American Journal of Pathology, 2004, 165, 181-189.	3.8	34
41	Different Susceptibility to Lung Tumorigenesis in Mice with an IdenticalKras2Intron 2. Genomics, 1995, 29, 438-444.	2.9	33
42	Genetics of liver tumor susceptibility in mice. Toxicology Letters, 1995, 82-83, 613-619.	0.8	28
43	A cancer modifier role for parathyroid hormone-related protein. Oncogene, 2000, 19, 5324-5328.	5.9	28
44	Circulating free DNA in a screening program for early colorectal cancer detection. Tumori, 2014, 100, 115-21.	1.1	27
45	CTAB-Urea Method Purifies RNA from Melanin for cDNA Microarray Analysis. Pigment Cell & Melanoma Research, 2004, 17, 312-315.	3.6	26
46	Pas1 is a common lung cancer susceptibility locus in three mouse strains. Mammalian Genome, 1997, 8, 801-804.	2.2	25
47	ERG Deregulation Induces PIM1 Over-Expression and Aneuploidy in Prostate Epithelial Cells. PLoS ONE, 2011, 6, e28162.	2.5	25
48	Analysis of loss of heterozygosity in murine hepatocellular tumors. Molecular Carcinogenesis, 1995, 13, 191-200.	2.7	23
49	Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy. Oncolmmunology, 2020, 9, 1774298.	4.6	22
50	Comparative Mapping of the Actin-Binding Protein 280 Genes in Human and Mouse. Genomics, 1994, 21, 428-430.	2.9	21
51	Mapping of the Hmg1 gene and of seven related sequences in the mouse. Mammalian Genome, 1995, 6, 581-585.	2.2	21
52	Gene expression profile identifies a rare epithelioid variant case of pleomorphic liposarcoma carrying FUS-CHOP transcript. Histopathology, 2005, 46, 334-341.	2.9	21
53	miR-342 overexpression results in a synthetic lethal phenotype in <i>BRCA1</i> -mutant HCC1937 breast cancer cells. Oncotarget, 2016, 7, 18594-18604.	1.8	20
54	Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer. Endocrine-Related Cancer, 2008, 15, 439-449.	3.1	16

#	Article	IF	CITATIONS
55	Regulation of lipocalin-2 gene by the cancer chemopreventive retinoid 4-HPR. International Journal of Cancer, 2006, 119, 1599-1606.	5.1	15
56	Combined analysis of chromosomal instabilities and gene expression for colon cancer progression inference. Journal of Clinical Bioinformatics, 2014, 4, 2.	1.2	15
57	NqA: An R-based algorithm for the normalization and analysis of microRNA quantitative real-time polymerase chain reaction data. Analytical Biochemistry, 2014, 461, 7-9.	2.4	15
58	Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells. Oncogene, 2007, 26, 3952-3962.	5.9	14
59	Predisposition to lung tumorigenesis. Toxicology Letters, 2000, 112-113, 257-263.	0.8	13
60	Gene expression profiling integrated into network modelling reveals heterogeneity in the mechanisms of BRCA1 tumorigenesis. British Journal of Cancer, 2009, 101, 1469-1480.	6.4	13
61	Genetic Mapping of the Mouse CDC25Mm Gene, a Ras-Specific Guanine Nucleotide-Releasing Factor, to Chromosome 9. Genomics, 1994, 21, 451-453.	2.9	12
62	Force Sensing on Cells and Tissues by Atomic Force Microscopy. Sensors, 2022, 22, 2197.	3.8	12
63	Transcriptional characteristics of familial nonâ€ <i>BRCA1/BRCA2</i> breast tumors. International Journal of Cancer, 2011, 128, 2635-2644.	5.1	11
64	Copy–Number Alterations for Tumor Progression Inference. Lecture Notes in Computer Science, 2013, , 104-109.	1.3	11
65	Gene expression profile of normal lungs predicts genetic predisposition to lung cancer in mice. Carcinogenesis, 2003, 24, 1819-1826.	2.8	10
66	Re: Limits of Predictive Models Using Microarray Data for Breast Cancer Clinical Treatment Outcome. Journal of the National Cancer Institute, 2005, 97, 1851-1852.	6.3	10
67	Methylation status in patients with early stage colon cancer: A new prognostic marker?. International Journal of Cancer, 2012, 130, 488-489.	5.1	10
68	A Pilot Low-Inflammatory Dietary Intervention to Reduce Inflammation and Improve Quality of Life in Patients With Familial Adenomatous Polyposis: Protocol Description and Preliminary Results. Integrative Cancer Therapies, 2019, 18, 153473541984640.	2.0	10
69	Genetic mapping and expression analysis of the murine DNA ligase I gene. Molecular Carcinogenesis, 1995, 14, 71-74.	2.7	9
70	Analysis of loss of heterozygosity in neoplastic nodules induced by diethylnitrosamine in the resistant BFF1 rat strain. Carcinogenesis, 1999, 20, 1363-1368.	2.8	9
71	Allele-specific patterns of the mouse parathyroid hormone-related protein: influences on cell adhesion and migration. Oncogene, 2003, 22, 7711-7715.	5.9	8
72	Specific gene expression profiles distinguish among functional allelic variants of the mouse Pthlh gene in transfected human cancer cells. Oncogene, 2006, 25, 4501-4504.	5.9	8

MANUELA GARIBOLDI

#	Article	IF	CITATIONS
73	A normalization strategy for the analysis of plasma microRNA qPCR data in colorectal cancer. International Journal of Cancer, 2014, 134, 2016-2018.	5.1	8
74	Preventive Anti-inflammatory Diet to Reduce Gastrointestinal Inflammation in Familial Adenomatous Polyposis Patients: A Prospective Pilot Study. Cancer Prevention Research, 2021, 14, 963-972.	1.5	8
75	Expression in lung tumors and genetic mapping of the novel murine protein kinase Cî•. Molecular Carcinogenesis, 1994, 9, 111-113.	2.7	4
76	Molecular markers for prediction of risk of radiation-related injury to normal tissue. Journal of Nucleic Acids Investigation, 2010, 1, 11.	0.8	4
77	Invasiveness gene signature predicts a favorable outcome also in estrogen receptor-positive primary breast cancers treated with adjuvant tamoxifen. Breast Cancer Research and Treatment, 2008, 111, 389-390.	2.5	3
78	Abstract 1161: Metformin has an inhibitory effect on cell proliferation but does not induce death in colorectal cancer. , 2015, , .		3
79	Integration of genome scale data for identifying new players in colorectal cancer. World Journal of Gastroenterology, 2016, 22, 534.	3.3	3
80	Esophageal Carcinoma. Acta Radiologica, 1987, 28, 177-180.	1.1	2
81	Chromosome mapping of nine tropomyosin-related sequences in mice. Mammalian Genome, 1995, 6, 273-277.	2.2	2
82	Analysis of the retinoic acid receptor α gene as a candidate for the pulmonary adenoma resistance 1 gene. Molecular Carcinogenesis, 1998, 21, 13-16.	2.7	2
83	RESPONSE: Re: Limits of Predictive Models Using Microarray Data for Breast Cancer Clinical Treatment Outcome. Journal of the National Cancer Institute, 2005, 97, 1852-1853.	6.3	2
84	Re: Molecular Basis for Estrogen Receptor Deficiency in BRCA1-Linked Breast Cancer. Journal of the National Cancer Institute, 2008, 100, 752-753.	6.3	2
85	Molecular markers for prediction of risk of radiation-related injury to normal tissue. Journal of Nucleic Acids Investigation, 2010, 1, 11.	0.8	2
86	Moving from Discovery to Validation in Circulating microRNA Research. International Journal of Biological Markers, 2015, 30, 258-261.	1.8	2
87	Comment on â€~Circulating cell-free miRNAs as biomarker for triple-negative breast cancer'—Methodological challenges in combining miRNAs as circulating biomarkers. British Journal of Cancer, 2016, 114, e5-e5.	6.4	2
88	Management of Dietary Habits and Diarrhea in Fap Individuals: A Mediterranean Low-Inflammatory Dietary Intervention. Nutrients, 2021, 13, 3988.	4.1	2
89	Esophageal Carcinoma. Acta Radiologica, 1987, 28, 177-180.	1.1	1
90	Workflow for Circulating miRNA Identification and Development in Cancer Research: Methodological Considerations. , 2018, , 103-117.		1

#	Article	IF	CITATIONS
91	Genetic mapping and analysis of mouse p27 Kip1 gene as Pas1 candidate gene. Mammalian Genome, 2000, 11, 338-339.	2.2	0
92	Abstract 4038: Identification of microRNAs involved in colorectal cancer progression. , 2010, , .		0
93	Abstract 3959: Growth suppression by TGF- \hat{l}^2 in responsive colon carcinoma is opposed by miR-20a through mechanisms altering p21WAF1 up-regulation. , 2011, , .		0
94	Abstract 2295: miR-342 modulates ID4 expression in breast cancer. , 2012, , .		0
95	Abstract CT121: Metronomic capecitabine and bevacizumab is an active combination in patients with relapsed peritoneal pseudomyxoma. , 2015, , .		0
96	Abstract B19: Disruption of energy homeostasis as an approach to block the proliferation of colon carcinomatosis. , 2017, , .		0
97	Exploring the association with disease recurrence of miRNAs predictive of colorectal cancer. International Journal of Biological Markers, 2022, 37, 102-109.	1.8	0